| Authors: |
Bill A; Novartis Institute for Biochemical Research, Oncology, Cambridge, MA, USA. anke.bill@novartis.com., Espinola S; Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA., Guthy D; Novartis Institute for Biochemical Research, Oncology, Basel, Switzerland., Haling JR; Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA.; Mirati Therapeutics, Inc., Research, San Diego, CA, USA., Lanter M; Novartis Institute for Biochemical Research, Oncology, Basel, Switzerland., Lu M; Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA., Marelli A; Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA., Mendiola A; Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA., Miraglia L; Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA., Taylor BL; Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA., Vargas L; Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA., Orth AP; Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA., King FJ; Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA. fred.king@novartis.com. |
